Marisa Bittoni, PhDLung Cancer | February 22, 2024
Marisa Bittoni, PhD, talks about a large-scale study exploring factors that lead to lung cancer in patients younger than 50.
View More
Cynthia Miller, MDLipid Management | February 21, 2024
Cynthia Miller, MD, MPH, FACP, discusses why early Lp(a) screening may help prevent cardiovascular disease.
Patrick DalySickle Cell Disease | February 13, 2024
Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease.
Pavlos Msaouel, MD, PhDOncology | February 12, 2024
What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib?
John Strouse, MD, PhDSickle Cell Disease | February 15, 2024
Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading.
Patrick DalySickle Cell Disease | February 8, 2024
Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic.
Dr. Mark BleackleyRheumatology | February 2, 2024
Incannex announces the first dosing in a phase 2 study of a novel drug combination comprising HCQ and CBD to treat RA.
Ashley GainesBreast Cancer | January 18, 2024
The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer.
Patrick DalyMyelofibrosis | February 16, 2024
Dr. Hobbs shared findings supporting the safety and feasibility of continuing ruxolitinib during and after HSCT for MF.
Christopher Lieu, MDASCO GI 2024 | January 23, 2024
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024.
Dr. Richard LafayetteChronic Kidney Disease | February 5, 2024
Dr. Richard Lafayette discusses the FDA approval of TARPEYO, which reduces the loss of kidney function in IgA nephropathy.
Hady Lichaa, MDPractice Tips With Dr. Lichaa | January 10, 2024
Dr. Lichaa describes the use of a transfusion filter to return filtered blood to a patient through a central access point.
Hana Safah, MDMDS | February 8, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDMDS | February 8, 2024
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDMDS | February 8, 2024
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDMDS | February 8, 2024
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Hana Safah, MDMDS | February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Hana Safah, MDMDS | February 8, 2024
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
Hana Safah, MDMDS | February 8, 2024
The panel discusses the evolution of MDS therapy and how the MEDALIST trial set the stage for luspatercept.
Hana Safah, MDMDS | February 8, 2024
Dr. Safah gave an overview of myelodysplastic syndromes.
Latest News

February 22, 2024